STX2 and hemolytic-uremic syndrome: Furthermore, Stx2 and LPS treatment activates coagulation/fibrinogenesis pathways, as indicated by increased plasma thrombin-antithrombin III (TAT) complex, fibrinogen and plasminogen activator inhibitor-1(PAI-1) levels and decreased platelet counts [9], [23], all of which have also been detected in human HUS patients [25], [26], [27].